Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other research firms also recently commented on RGEN. Evercore ISI assumed coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Monday, May 5th. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. Royal Bank of Canada decreased their price target on Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group reduced their price objective on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

Repligen Trading Down 3.6 %

NASDAQ:RGEN opened at $123.24 on Thursday. The firm’s 50 day moving average is $135.03 and its 200 day moving average is $145.32. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The stock has a market capitalization of $6.92 billion, a PE ratio of -241.65, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 EPS. Sell-side analysts expect that Repligen will post 1.72 earnings per share for the current year.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Repligen

Several hedge funds have recently added to or reduced their stakes in RGEN. Signaturefd LLC grew its position in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new stake in Repligen during the 4th quarter valued at $29,000. Raiffeisen Bank International AG purchased a new stake in Repligen during the 4th quarter valued at $29,000. Itau Unibanco Holding S.A. bought a new stake in Repligen in the 4th quarter worth $40,000. Finally, Center for Financial Planning Inc. increased its position in shares of Repligen by 110.3% in the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 193 shares during the period. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.